On December 13, 2021, Eric Sawyer filed this petition with the Department of Health and Human Services, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by… Continue Reading
(Update: On December 15, 2021 KEI hosted a press briefing regarding the Xtandi march-in request. Video and details available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) On November 18, 2021, Robert Sachs and Clare Love submitted a petition to the Secretary of Health and Human… Continue Reading
November 10, 2021 Andrew Burke, Ph.D. Senior Technology Transfer Manager, NCI Technology Transfer Center, Email: andy.burke@nih.gov. Re: Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer to Neogene Therapeutics… Continue Reading
UPDATE: On Friday, 12 November 2021, the draft report of the Member States Working Group on Strengthening WHO Preparedness for and Response to Health Emergencies (WGPR) was published with the document number, A/WGPR/5/2. The report is available here. The fifth… Continue Reading
Update: On 28 October 2021 the Zero Draft Report of the Member States Working Group on Strengthening WHO Preparedness for and Response to Health Emergencies to the special session of the World Health Assembly was published with the Document number… Continue Reading
(For more resources, please see our page on molnupiravir.) The Medicines Patent Pool (MPP) and Merck Sharp & Dohme (“MSD” or “Merck”) have announced a voluntary license for the generic manufacture and sale of molnupiravir. A joint press release from… Continue Reading
(For more resources, please see our page on molnupiravir.) According to Brook Baker, these are the countries included in the Merck voluntary license to generic suppliers Afghanistan, Algeria, Angola, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon,… Continue Reading
(For more resources, please see our page on molnupiravir.) KEI has built a dataset of patents related to molnupiravir based upon a study by Imran et al (2021), the Medicines Patent Pool (MPP) MedsPal database, and our own searches. Our… Continue Reading
(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading
Also known as EIDD-2801 or MK-4482. KEI Blogs 2021. October 22. Countries included in the Merck/molnupiravir license. 2021. October 20. International landscape of molnupiravir patents. 2021. October 4. U.S. Government’s $1.2 Billion Contract for Merck’s Investigational COVID-19 Drug Molnupiravir Redacts… Continue Reading